ASTCOQ02
ASTCOQ02 has been studied in 1 paper since 2025: 1 trial in people. The newest paper, Feb 7, 2025: “The Effect of Telomerase Activator ASTCOQ02 on Cognitive Factors in Middle-Aged Adults: A randomized Double-Bling Study”.
1 paper studies it3 findingsUpdated
“showed significant improvements in cognitive metrics, including reduced P300 latency”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Agence Nationale de Sécurité du Médicament et des Produits de Santé
- Human trial1
Studies in people
1 study gave ASTCOQ02 to people and measured what changed.
up: Improves cognitive functionP300 latency 274.1 ± 17.5 ms at baseline vs. 262.4 ± 19.2 ms at six months; p = 0.017
up: Increases median telomere length9.81 ± 0.82 kb to 10.28 ± 0.88 kb; p = 0.008
no change: Has no effect on plasma antioxidant capacity
Randomized trial40 peoplemean 56.1 ± 6.0 yearssix months
Midlife adults; placebo-controlled trial; P300 latency and Rey's 15-word test
Preprints.org, Feb 7, 2025
What did studies of ASTCOQ02 find?
3Studies of ASTCOQ02 measured 3 outcomes; the most studied are plasma antioxidant capacity (1 study), median telomere length (1) and cognitive function (1).
Plasma antioxidant capacity
no changein humans1
1 study
Plasma antioxidant capacity
no changein humans1
ASTCOQ02 showed no clear effect on plasma antioxidant capacity in humans (placebo-controlled trial).
“Antioxidant capacity remained unchanged.”
Human trialplacebo-controlled trialsix monthsn = 40
Preprints.orgPreprint
Median telomere length
upin humans1
1 study
Median telomere length
upin humans1
ASTCOQ02 increases median telomere length in humans (placebo-controlled trial) (9.81 ± 0.82 kb to 10.28 ± 0.88 kb; p = 0.008).
“Telomerase activation was evidenced by an increase in median telomere length (9.81 ± 0.82 kb to 10.28 ± 0.88 kb; p = 0.008)”
Human trialplacebo-controlled trialsix monthsn = 40
Preprints.orgPreprint
Cognitive function
upin humans1
1 study
Cognitive function
upin humans1
ASTCOQ02 improves cognitive function in humans (placebo-controlled trial; P300 latency and Rey's 15-word test) (P300 latency 274.1 ± 17.5 ms at baseline vs. 262.4 ± 19.2 ms at six months; p = 0.017).
“showed significant improvements in cognitive metrics, including reduced P300 latency”
Human trialplacebo-controlled trial; P300 latency and Rey's 15-word testsix monthsn = 40
Preprints.orgPreprint